Viscosupplementation Market Size To Reach $9.39 Billion By 2033

Viscosupplementation Market Growth & Trends

The viscosupplementation market size is estimated to reach USD 9.39 billion by 2033, expanding at a CAGR of 6.21% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market growth is driven by several key factors, including a rise in the elderly population, an increase in osteoarthritis cases among older individuals, and substantial investments in research and development. According to the CDC, approximately 25% of adults in the United States currently experience some type of arthritis, and this number is expected to reach 78 million by 2040. As a result, the demand for viscosupplementation is predicted to surge in the coming years.

Furthermore, the market growth is being propelled by the increasing adoption of key strategies, such as acquisition, agreement, collaboration, and partnership, by companies. For instance, in December 2021, Avanos Medical, a medical technology company, acquired OrthogenRx, Inc., a trailblazer in viscosupplementation therapy for knee osteoarthritis treatment. The acquisition amounted to approximately USD 160 billion. Avanos utilizes FDA-approved products, such as TriVisc and GenVisc850, to provide effective solutions in this field. Moreover, favorable reimbursement policies with respect to the geriatric population are expected to act as an opportunity for market growth.

Over the past few years, there has been a remarkable increase in the number of orthopedic surgeons in developing nations like South Korea, Russia, and China. This trend indicates significant growth potential in the Asia Pacific region, which boasts a large patient population and untapped opportunities when compared to the United States. Consequently, the introduction of new products by market players in Asian countries is anticipated to drive further growth in the market.

 Request a free sample copy or view report summary: Viscosupplementation Market Report

Viscosupplementation Market Report Highlights

• The three-injection segment is anticipated to grow at the significant CAGR over the forecast period.

• The single injection viscosupplementation procedure dominated with a revenue share of 43.44% in 2024

• The orthopedic clinics/ambulatory surgical centers (ASCs) dominated the segment with a revenue share of 63.06% in 2024. Their facilities, which provide outpatient services, remain more feasible for the geriatric population. The segment is expected to continue its dominance throughout the forecast period

• Asia Pacific dominated the market and accounted for the largest revenue share of 45.82% in 2024 due to its large geriatric population

• Europe viscosupplementation market is anticipated to grow at the fastest rate over the forecast period due to medical advancements and the presence of untapped opportunities. The region is also forecasted to witness a growth in its geriatric population, resulting in more cases of osteoarthritis

Viscosupplementation Market Segmentation

Grand View Research has segmented the viscosupplementation market based on product, end use, and region:

Viscosupplementation Product Outlook (Revenue in USD Billion, 2021 - 2033)

• Single Injection

• Three Injection

• Five Injection

Viscosupplementation End Use Outlook (Revenue, USD Billion, 2021 - 2033)

• Hospitals

• Orthopedic Clinics/ASCs

Viscosupplementation Regional Outlook (Revenue, USD Billion, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • France

  • Germany

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Viscosupplementation Market

• DePuy Synthes

• Fidia Farmaceutici S.p.A

• Sanofi

• Smith & Nephew PLC

• Anika Therapeutics, Inc.

• Seikagaku Corp.

• Zimmer Biomet

• Ferring Pharmaceuticals B.V.

• Lifecore Biomedical

• LG Life Sciences Ltd.

• F.Hoffmann-La Roche Ltd.